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Abstract
Melatonin	receptors	(nomenclature	as	agreed	by	the	NC-IUPHAR	Subcommittee	on	Melatonin
Receptors	[40])	are	activated	by	the	endogenous	ligands	melatonin	and	clinically	used	drugs	like
ramelteon,	agomelatine	and	tasimelteon.
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This	is	a	citation	summary	for	Melatonin	receptors	in	the	Guide	to	Pharmacology	database	(GtoPdb).
It	exists	purely	as	an	adjunct	to	the	database	to	facilitate	the	recognition	of	citations	to	and	from	the
database	by	citation	analyzers.	Readers	will	almost	certainly	want	to	visit	the	relevant	sections	of	the
database	which	are	given	here	under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[20].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
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